IPHA Stock Analysis: Buy, Sell, or Hold?
IPHA - Innate Pharma S.A. ADS
$1.91
0.12 (6.70%)
▲
5d:
+5.52%
30d:
+9.14%
90d:
+52.8%
BUY
MODERATE Confidence
Analysis Updated: Jun 25, 2026 12:00 AM ET
Earnings: Sep 17, 2026
Get Alerted When IPHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IPHA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IPHA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IPHA is currently trading at $1.91, which is considered slightly high relative to its 30-day fair value range of $1.71 to $1.97.
Technical Outlook: Technically, IPHA is showing sideways momentum. The price is approaching resistance at $1.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.7% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+235.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IPHA is showing sideways momentum. The price is approaching resistance at $1.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.7% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+235.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.71 -
$1.97
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.1%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.7%)
- BULLISH: Trading 235.2% below Wall St target ($6.00)
Trading Range Analysis
30-Day Trading Range
$1.71 -
$1.97
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.71
Resistance Level
$1.92
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.82
Wall Street Target
$6.00
(+235.2%)
Revenue Growth (YoY)
-46.7%
Earnings Growth (YoY)
-74.7%
Share & Embed Analysis
Last updated: June 26, 2026 12:04 PM ET
Data refreshes hourly during market hours. Next update: 1:04 PM
Data refreshes hourly during market hours. Next update: 1:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IPHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 52 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 64 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 58 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 62 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 59 HOLD |
